Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Significant Growth in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Rating) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 719,600 shares, an increase of 5.1% from the February 13th total of 685,000 shares. Based on an average daily volume of 302,000 shares, the short-interest ratio is presently 2.4 days. Currently, 1.6% of the company’s shares are sold short.

Alzamend Neuro Stock Performance

Alzamend Neuro stock opened at $0.48 on Thursday. Alzamend Neuro has a 1 year low of $0.47 and a 1 year high of $1.50. The company’s 50-day moving average is $0.59 and its two-hundred day moving average is $0.90.

Institutional Trading of Alzamend Neuro

A number of institutional investors and hedge funds have recently modified their holdings of ALZN. Vanguard Group Inc. increased its stake in Alzamend Neuro by 6,642.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,095,775 shares of the company’s stock worth $4,874,000 after purchasing an additional 4,035,028 shares in the last quarter. BlackRock Inc. bought a new stake in Alzamend Neuro during the 3rd quarter worth approximately $709,000. Renaissance Technologies LLC bought a new stake in Alzamend Neuro during the 2nd quarter worth approximately $56,000. Virtu Financial LLC bought a new stake in Alzamend Neuro during the 4th quarter worth approximately $35,000. Finally, HRT Financial LP bought a new stake in Alzamend Neuro during the 4th quarter worth approximately $32,000. 0.95% of the stock is owned by institutional investors.

About Alzamend Neuro

(Get Rating)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.